Inactive Instrument

News Tokai Pharmaceuticals Inc Nasdaq

Equities

US88907J1079

Biotechnology & Medical Research

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook	Jan. 13	GL
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook	Jan. 13	AQ
Eledon Pharmaceuticals : Announces Recent Business Highlights and Third Quarter 2024 Financial Results Form 8 K	Nov. 12	PU
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results	Nov. 12	GL
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference	Nov. 06	GL
Eledon Pharmaceuticals : Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre Funded Warrants Form 8 K	24-10-30	PU
Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise	24-10-29	MT
Eledon Pharmaceuticals : Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator Initiated Trial at UChicago Medicine Form 8 K	24-10-29	PU
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	24-10-29	GL
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	24-10-29	AQ
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine	24-10-29	GL
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine	24-10-29	AQ
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial At UChicago Medicine	24-10-29	CI
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference	24-09-11	GL
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients	24-09-04	GL
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients	24-09-04	AQ
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients	24-09-04	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-19	CI
Eledon Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	24-08-18	CI
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results	24-08-14	GL
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection	24-07-29	GL
Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection	24-07-29	CI
Eledon Pharmaceuticals : Submission of Matters to a Vote of Security Holders Form 8 K	24-07-10	PU
Eledon Pharmaceuticals, Inc. announced that it has received $2.099993 million in funding	24-07-07	CI

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tokai Pharmaceuticals Inc Nasdaq

Equities

US88907J1079

Biotechnology & Medical Research

Filters